Small molecule · Activator of KCNQ2 potassium channel (Kv7.2) (KCNQ2), KCNQ3 potassium channel (Kv7.3) (KCNQ3) and KCNQ4 potassium channel (Kv7.4) (KCNQ4) · developed by Glaxosmithkline
Ezogabine (retigabine) is a small-molecule potassium channel opener that enhances transmembrane currents through KCNQ (Kv7.2 to 7.5) channels, stabilizing the resting membrane potential and reducing brain excitability. It is studied in epilepsy, including pediatric epilepsy.
Summary written with AI from the sources listed at the end of this page.
From the indications section of the FDA label (version of May 20, 2016). Read the full label for the exact wording, limitations and safety information.
| Trial | Phase | Condition | Status | Sponsor |
|---|---|---|---|---|
| NCT04912856 | Phase 3 | Epilepsy | Terminated | XENE |
Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.
Brain DiseasesCentral Nervous System DiseasesDiseaseEpilepsyEpilepsy in ChildrenEpilepsy; SeizureEpileptic SyndromesNervous System Diseases
Updated Nov 1, 2026.